Skip to main content
. Author manuscript; available in PMC: 2018 Jan 18.
Published in final edited form as: Sci Transl Med. 2017 Jan 18;9(373):eaai8030. doi: 10.1126/scitranslmed.aai8030

Fig. 2. The collagen IV–derived peptide AXT107 suppresses VEGF-induced subretinal NV and ischemia-induced retinal NV.

Fig. 2

(A) At P14, rho/VEGF transgenic mice in which the rhodopsin promoter drives expression of VEGF in photoreceptors were given an intraocular injection of 0.1 or 1 μg of AXT107 or 1 μg of control peptide. At P21, the area of subretinal NV on GSA-stained retinal flat mounts oriented with photoreceptor side up was measured. (B) At P12, C57BL/6 mice with OIR were given an intraocular injection of 0.1 or 1 μg of AXT107 or 1 μg of control peptide. At P17, retinas were incubated for 40 min with GSA, which selectively stains NV (patches of dark green) and hyaloid vessels (snake-like structures) and does not stain preexisting retinal vessels. Bars represent mean (± SEM). **P < 0.01, ***P < 0.001 for difference from control by ANOVA with Bonferroni correction for multiple comparisons.